Dipeptidyl peptidase-IV (DPP-IV) Inhibitors – a promising oral anti-diabetic drug

Authors

  • Seema Manak Facilty of Dentistry Jamia Millia Islamia, New Delhi, India
  • F. Akram
  • D. Inder

Keywords:

Dipeptidyl peptidase IV inhibition, incretin, gliptin, oral antidiabetic drugs

Abstract

Dipeptidyl-peptidase IV (DPP-4) inhibitors inhibit the degradation of the incretins i.e glucagon-like peptide1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). Incretins augment the insulin release by a blood glucose-dependent mechanism. Generally DPP-IV enzyme is responsible for inactivating incretins and this enzyme inhibition will prolong and enhance the activity of GLP-1 and GIP. DPP-IV inhibitors increase post prandial insulin secretion, decreases glucagon secretion and seems to have beneficial effect on cardiovascular system, renal and hepatic insufficiencies. Being safe, tolerable and able to maintain consistent glycemic control without severe hypoglycemia and weight gain makes it unique and valuable in pharmacotherapy of Type 2 diabetes mellitus.

 

Keywords: Dipeptidyl peptidase IV inhibition, incretin, gliptin, oral antidiabetic drugs, Type-2 diabetes mellitus

 

Cite this Article

S. Manak, F. Akram, D. Inder. Dipeptidyl peptidase-IV (DPP-IV) Inhibitors – a promising oral anti-diabetic drug. Research & Reviews: A Journal Pharmaceutical Science. 2020; 11(3): 1–6p.

Author Biography

  • Seema Manak, Facilty of Dentistry Jamia Millia Islamia, New Delhi, India

    Department of Pharmacology

    Associate Professor

Downloads

Published

2021-01-05

Issue

Vol. 11 No. 3 (2020)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.